- Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
- Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
- Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
- Insulet to Present at the Jefferies Global Healthcare Conference
- Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
- Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
More ▼
Key statistics
On Tuesday, Insulet Corp (PODD:NSQ) closed at 197.19, 56.72% above the 52 week low of 125.82 set on Oct 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 199.33 |
---|---|
High | 202.20 |
Low | 195.80 |
Bid | 193.00 |
Offer | 205.00 |
Previous close | 196.16 |
Average volume | 785.58k |
---|---|
Shares outstanding | 70.04m |
Free float | 69.80m |
P/E (TTM) | 61.07 |
Market cap | 13.74bn USD |
EPS (TTM) | 3.21 USD |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼